Epithalon: a pineal peptide, a telomere claim and a replication gap

Four amino acids and a big promise

In 2003, a one-page paper in a Russian biology journal made a claim that would echo through anti-ageing circles for two decades. A peptide of just four amino acids, the authors reported, could switch on telomerase in normal human cells and lengthen their telomeres ^[2].

Telomeres are the protective caps at the ends of chromosomes, a bit like the plastic tips on shoelaces. They wear down each time a cell divides, and short telomeres are linked to ageing and age-related disease ^[9]. Telomerase is the enzyme that can rebuild them. A cheap, simple molecule that turned it on would be a remarkable thing.

That is why Epithalon draws so much interest. The harder question, and the one this article tries to answer fairly, is how much of the evidence has been confirmed by anyone outside the group that created it.

Origin: Khavinson and the bioregulator school

The story starts with epithalamin, a polypeptide extract made from the pineal glands of cattle ^[11]. The pineal gland is the small structure in the brain that produces melatonin. Researchers at the St Petersburg Institute of Bioregulation and Gerontology, led by Vladimir Khavinson, studied epithalamin and a thymus extract, thymalin, in older people over many years ^[1]. Epithalamin has been described as a pharmacopoeia drug ^[7].

Epithalon came next. It is a synthetic tetrapeptide designed from the amino-acid composition of epithalamin, but it is a different, chemically defined substance, and results from one cannot simply be transferred to the other ^[11]. The earliest indexed papers on it appeared in 2000, including a fruit-fly study ^[6].

How a pineal peptide is thought to work

Two main ideas run through the literature. The first is telomere maintenance: the peptide is reported to raise expression of hTERT, the catalytic part of telomerase, so cells can rebuild their chromosome tips ^[2,9]. The second is neuroendocrine: in older animals and people it is reported to restore the night-time rise in melatonin, which helps set the body clock ^[7,8].

Both ideas share a gap. Nobody has established how a peptide this small reaches the right compartments of the cell, how long it lasts in the body, or what dose range is active. A 2026 review judged the pharmacokinetic and dose-ranging data inadequate ^[11].

What the research shows

Telomerase in cell culture

The 2003 study added Epithalon to cultures of telomerase-negative human fetal fibroblasts. The authors reported expression of telomerase's catalytic subunit, measurable enzyme activity and telomere elongation ^[2]. A 2004 follow-up used fetal lung fibroblasts that normally stopped dividing at around passage 34. Treated cells made 10 extra divisions, reaching passage 44, and kept dividing ^[3].

In 2025, a team at Brunel University London, with no stated links to the St Petersburg group, tested the claim independently ^[9]. In normal fibroblasts and epithelial cells, Epithalon produced dose-dependent telomere lengthening through higher hTERT expression and telomerase activity. In two breast cancer cell lines, it lengthened telomeres by a different route, alternative lengthening of telomeres (ALT), raising ALT activity about 10-fold in one line and 3-fold in the other ^[9]. A correction later replaced three of the paper's figures ^[10].

Lifespan in animals

In fruit flies, adding Epithalon to the larval food increased adult lifespan by 11–16%, and the effect did not depend on dose ^[6].

In female mice, 54 per group, monthly courses from 3 months of age until death did not change food intake, body weight or mean lifespan ^[4]. Treated mice did show a 13.3% longer lifespan among the last 10% of survivors, a 12.3% longer maximum lifespan, 17.1% fewer chromosome aberrations in bone marrow and six times less leukaemia, while total tumour rates were unchanged ^[4].

In the best-known mouse study, Epithalon did not change average lifespan at all. The headline gains came from the longest-lived tenth of the animals ^[4].

In male rats housed under different light regimes, treatment from 4 months of age until death barely changed mean lifespan. It was associated with a slower rate of population ageing under natural or constant light and with fewer spontaneous tumours ^[5].

Melatonin and the body clock

Old rhesus monkeys, aged 20 to 27, had lower night-time melatonin and higher glucose and insulin than young monkeys aged 6 to 8. Epithalon raised night melatonin and improved glucose handling in the old animals and had no effect in the young ^[7]. A small human study compared 15 older adults on Epithalon, 15 on epithalamin and 10 on placebo. Night melatonin rose mainly in people whose pineal function was low to begin with ^[8,11].

Human outcomes

The most quoted human figures concern epithalamin, not Epithalon. In older people followed for 6 to 8 years, the St Petersburg and Kyiv researchers reported 1.6- to 1.8-fold lower mortality in the epithalamin group than in controls ^[1]. These reports predate modern trial standards, and no adequately powered randomised trial of Epithalon has established any clinical benefit ^[11].

What we don't know yet

Science usually trusts a striking finding once unrelated labs have reproduced it. By that standard, Epithalon is still waiting. Nearly all the published work comes from Khavinson's institute and close collaborators ^[11]. Many key papers appeared in journals with modest international reach, such as Bulletin of Experimental Biology and Medicine and the Russian-language Advances in Gerontology ^[2,3,5,8]. None of this makes the findings wrong. It means they are less tested than their fame suggests.

• Independent replication. The one clearly independent study is a cell-culture experiment, and part of its data had to be corrected ^[9,10].
• Human evidence. Human data are limited to small biomarker studies and older reports that may involve overlapping patient groups ^[11].
• The cancer question. Telomere maintenance is a double-edged sword, because cancer cells need it to keep dividing. The Brunel team saw telomere lengthening in cancer cell lines ^[9], while the St Petersburg mouse study reported less leukaemia ^[4]. A 2026 review called the cancer-related uncertainties unresolved ^[11].
• Pharmacology. How it is absorbed, distributed and cleared, and what doses matter, are not established ^[11].
• Long-term safety. Adequate long-term safety data do not exist ^[11].

Regulatory status

• Medicine status: Epithalon is not approved as a medicine by the FDA ^[11], and we found no marketing authorisation in the EU.
• FDA compounding review (2026): On 24 July 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed Epithalon (free base and acetate) for the 503A bulk substances list, for the nominated use of insomnia ^[12]. The panel voted in favour by a narrow margin ^[13], although FDA briefing materials had recommended against inclusion ^[11]. The vote is advisory, and at the time of writing (October 2026) we found no final FDA decision.
• Epithalamin: The parent pineal extract is a separate product with its own history of clinical use in the region where it was developed ^[1,7].

In the lab: handling and storage

Epithalon is a small, highly polar peptide normally supplied as a lyophilised powder. Common practice is long-term storage at −20 °C, with 2–8 °C acceptable for short periods, protected from light and moisture. Lyophilised peptides absorb water from the air, so vials are best allowed to reach room temperature before opening. After reconstitution, many labs divide solutions into single-use aliquots to avoid freeze-thaw cycles. Our guide to storing research peptides covers the details, and the Epithalon product page lists the lot specifications.

FAQ